Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "XRCC1" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
DNA repair protein XRCC1 also known as X-ray repair cross-complementing protein 1 is a protein that in humans is encoded by the XRCC1 gene. XRCC1 is involved in DNA repair where it complexes with DNA ligase III.
Screening method of colorectal cancer treatment prognosis biomarkers
InactiveCN103324846AShorten screening timeReduce screening costsSpecial data processing applicationsDNA/RNA fragmentationKRASPrognosis biomarker
The invention discloses a screening method of colorectal cancer treatment prognosis biomarkers. The screening method includes the following steps of: (1) making a primary search strategy for screening the biomarkers; (2) making a literature adopting and exclusion criterion; (3) analyzing data and primarily screening the biomarkers; (4) making evident grades; (5) making a high quality evident evaluation criterion; (6) performing grading retrieval and quality evaluation on biomarker clinic evident; (7) performing data analyzing and statistics on the biomarker clinic evident; (8) screening the prognosis biomarkers. The invention further provides the colorectal cancer treatment prognosis biomarkers obtained through screening according to the screening method, and the prognosis biomarkers include KRAS, TYMS, TYMS, EGFR, UGT1A1*28, DPYD, PIK3CA, ERCC1, PTEN, VEGFR, BRAF, GST P1, XRCC1, MTHFR, MSI and the like.
Owner:浙江加州国际纳米技术研究院绍兴分院
Genetic Screening for Polymorphisms in Human Genes that Increase or Decrease Sensitivity to Toxic Agents
InactiveUS20070207195A1Reduce exposureData processing applicationsMicrobiological testing/measurementGeographic regionsIncreased risk
Methods are disclosed for genetically counseling a person based on one or more polymorphisms in his or her genes that sensitize him or her to toxic agents. Methods are also disclosed for genetically screening a group of individuals and / or a human population, based on, for example, ethnicity, race, religion or geographic region, to identify individuals with such polymorphisms for counseling. The methods can be used to counsel a person who has not been genetically tested for polymorphisms but who might have increased risk for sensitivity to toxic agents due to his or her membership in a particular group and / or population. The methods use correlations between genotypes of polymorphic alleles in a panel of cell lines and sensitivity of the cell lines to toxic agents. As examples, the methods are used to identify genotypes of allelic forms of the genes TP53, OGG1, ERCC2, XRCC1, and NOS3 that increase sensitivity or resistance of cells to toxic agents.
Owner:APPLIED GENETICS DERMATICS
Gene detection kit for prognosing gastric cancer metastasis and use method of gene detection kit
InactiveCN106636366AThe result is objectiveOptimal treatment timeMicrobiological testing/measurementBreast cancer metastasisRAD51
The invention relates to a gene detection kit for prognosing gastric cancer metastasis. The kit comprises a DNA library building kit, wherein the DNA library building kit comprises a high-risk gene probe and a low-risk gene probe; the high-risk gene probe comprises CDH1, CDH2, SNAIL, SLUG, MUC4, MUC6, PRSS3, USP6, MLH1, MSH2, MSH6, PMS2, TGFBR2, MMP2, MMP9, BRCA1, BRCA2, PALB2, ATM, ATR, MUTYH, EMSY, ERCC4, RAD51, PARP1 and XRCC1; the low-risk gene probe comprises ATRX, BRIP1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FANCO, FANCP, MDM2, MDM4, MLH1, NPM1, PP2R1A, PRKDC, RAD50, STAG2, XRCC5 and CRCC6. The invention further discloses a use method of the kit. The use method comprises the following steps: extracting cfDNA in a blood sample; building a library for the cfDNA through the DNA library building kit, and then sequencing the DNA to obtain a gene overall length sequence; carrying out gene mutation analysis on the gene overall length sequence.
Owner:苏州首度基因科技有限责任公司 +1
Esophageal cancer genetic test kit
InactiveCN101608218AMicrobiological testing/measurementFluorescence/phosphorescenceFluorescenceNucleotide
The invention discloses a kit for testing the genetic risk of esophageal cancer, which comprises specific premier pairs for testing the single nucleotide polymorphic locus genotypes of a cytochrome P450 1A1 gene (CYP1A1), a cytochrome P450 2E1 gene (CYP2E1), a glutathione-S-transferase M1 gene (GSTM1), a 5,10-methylenetetrahydrofo late reductase gene (MTHFR), a reduction type coenzyme I quinone oxido-reductase gene (NQ01), an oncoprotein 53 gene (P53), an X-ray repair cross-complementing gene 1 (XRCC1) and a xeroderma pigmentosum complementary set A gene (XPA) as well as specific fluorescent probe pairs, fluorescent quantitative PCR regular components, PCR reaction components and the like. The kit of the invention estimates the individual genetic risk of esophageal cancer by synchronously testing the polymorphic locus genotypes of the genes closely related to the genetic risk of esophageal cancer.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Kit for detecting inheritance gene restoring capability
The invention discloses an agent box for detecting idiogenetics gene repair capacity. The agent box comprises specificity primer pair and specificity fluorescent detecting probe pair for detecting synchronously number rs1136410 SNP site on multi-poly ADP ribose transferase gene (PARP1), number rs1799782 and rs25487 SNP site on human beings X ray intervein complementation repair gene (XRCC1), number rs1799793 and rs13181 on cutting repair complexes gene (ERCC2), general component for detecting fluorescent definite quantity PCR etc.. The agent box of the invention assesses idiogenetics gene repair capacity by detecting synchronously mononucleotide polymorphism site gene type correlative closely to idiogenetics gene repair capacity.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Primer group, reagent and/or kit and system for detecting lung cancer chemotherapy related genes, and application
ActiveCN109517900AClustering is clearImprove accuracyMicrobiological testing/measurementDNA/RNA fragmentationCYP2C8Biology
The invention relates to a primer group, reagent and / or kit and system for detecting lung cancer chemotherapy related genes, and application. The primer group contains primers for detecting gene mutation of ERCC1, MTHFR, GSTP1, XRCC1, DYNC2H1, ABCB1, CYP2C8*3, TP53, NQO1, CBR3, SOD2, CYP2C19, UGT1A1*6, TYMS, NT5C2 and CDA. The primer group, the reagent and / or the kit, the system and the application have the advantages of high accuracy, high specificity, high sensitivity, good precision and the like, and meanwhile, further have the advantages of sample saving, short detection period, easy operation, convenient analysis and the like.
Owner:SIMCERE DIAGNOSTICS CO LTD +2
Pancreatic cancer genetic test kit
InactiveCN101608220AMicrobiological testing/measurementFluorescence/phosphorescenceFluorescenceNucleotide
The invention discloses a kit for testing the genetic risk of pancreatic cancer, which comprises specific primer pairs for testing the single nucleotide polymorphic locus genotypes of a 5,10-methylenetetrahydrofo late reductase gene (MTHFR), a xeroderma pigmentosum complementary set C gene (XPC), X-ray repair cross-complementing gene 1 (XRCC1) and a thymidylate synthase gene (TS) as well as specific fluorescent probe pairs, fluorescent quantitative PCR regular components, PCR reaction components and the like. The kit of the invention estimates the individual genetic risk of pancreatic cancer by synchronously testing the polymorphic locus genotypes of the genes closely related to the genetic risk of pancreatic cancer.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Primer for simultaneously detecting XRCC1, ERCC, GSTP1 and GSTM1 gene polymorphism, and method thereof
InactiveCN105039528AStrong specificityImprove accuracyMicrobiological testing/measurementSpecific detectionMedicine
The invention provides a primer for simultaneously detecting the XRCC1, ERCC, GSTP1 and GSTM1 gene polymorphism. The primer comprises a PCR amplification primer and an SNaPshot PCR primer, and belongs to the technical field of biological detection. The primer provided by the invention can realize specific detection of the XRCC1, ERCC, GSTP1 and GSTM1 gene polymorphism, has no cross reaction and has good accuracy.
Owner:GUANGZHOU KINGMED DIAGNOSTICS CENT +1
Kit for predicting lung cancer metastasis, and usage method of kit
InactiveCN106755322AGood repeatabilityMultiple treatment timesMicrobiological testing/measurementLymphatic SpreadLung cancer
The invention relates to a kit for predicting lung cancer metastasis, and a usage method of the kit. The kit comprises a DNA library kit which comprises probes of multiple genes, and the multiple genes comprise: high-risk genes: BRCA1, BRCA2, PALB2, ATM, ATR, MUTYH, EMSY, ERCC4, RAD51, PARP1 and XRCC1; and low-risk genes: ATRX, BRIP1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FANCO, FANCP, MDM2, MDM4, MLH1, NPM1, PP2R1A, PRKDC, RAD50, STAG2, XRCC5, XRCC6. Through performing related mutation detection to the related genes of DNA repair system signal paths, lung cancer metastasis can be rapidly and conveniently judged and predicted by combining a special rating mechanism.
Owner:苏州首度基因科技有限责任公司 +1
Primer and method for simultaneously detecting XRCC1, ERCC1 and GSTP1 gene polymorphisms
InactiveCN104988224AStrong specificityImprove accuracyMicrobiological testing/measurementDNA/RNA fragmentationSpecific detectionMedicine
The invention belongs to the technical field of biological detection, and provides a primer for simultaneously detecting XRCC1, ERCC1 and GSTP1 gene polymorphisms. The primer comprises a PCR amplification primer and a SNaPshot PCR primer. The primer can achieve specific detection on XRCC1, ERCC1 and GSTP1 gene polymorphisms, causes no cross reaction and is good in accuracy.
Owner:GUANGZHOU KINGMED DIAGNOSTICS CENT
Gene combination, primer and probe for detecting gastric cancer susceptibility and application
InactiveCN101962667AImprove accuracyImprove throughputMicrobiological testing/measurementDNA/RNA fragmentationXRCC1 GeneMetabolic enzymes
The invention discloses a gene combination, a primer and a probe for detecting gastric cancer susceptibility and application. The gene combination comprises a combination of four genes closely related with a gastric cancer, namely an MTHFR gene, a CYP2E1 metabolic enzyme gene, an XRCC1 repairase gene and an ADPRT repairase gene. The gene combination comprises the following SNP sites: rs1801133 site of the MTHFR gene, rs2031920 site of the CYP2E1 gene, rs25478 site of the XRCC1 gene and rs1136410 site of the ADPRT gene. Whether the detected crowds carry 'gastric cancer susceptible genes' are comprehensively detected and analyzed by detecting a group of genes and sites related with the gastric cancer susceptibility, using the specific primer and the probe and combining a mononucleotide extending technique and a micro array chip technique so as to screen the gastric cancer susceptible crowd from the crowds, change unhealthy lifestyles and fulfill the purpose of preventing.
Owner:NANJING WEIYU GENETIC ENG
Reagent kit for detecting lawful age females synthetic disease genetic susceptibility
InactiveCN101275911AMicrobiological testing/measurementChemiluminescene/bioluminescenceDiseaseFluorescence
The present invention discloses a reagent kit which detects the genetic susceptibility of the synthetic disease of adult woman. The reagent kit comprises a specific primer pair and a specific fluorescent probe pairs which simultaneously detects the SNP polymorphic genotype on the genes of CYBA, CAT, LPL, LEP, ADIPOQ, SOD3, IL3, NOS3, CTLA4, ENOS, ESR2, ERCC1, MTHFR, MS4A2, XRCC1, ALDH2, TNFA, MTR, CCL5, COMT, GSTP1, PPARG, PARP1, OPG, VDR, PON1, ABCA1, MTRR, ERCC2, AT1R, AGT, CCND1, UCP2, ADH2, ADBR2, APOB, CYP11B2, CYP1A1, CYP2E1, CETP, NQO1, IL6, CYP2A13, CBS, a routine component which is used for the fluorescent quantitative PCR testing and the like. The reagent kit of the invention evaluates the genetic susceptibility of the synthetic disease of adult woman through simultaneously detecting the mononucleotide polymorphism site genotype which is closely linked to the genetic susceptibility of the synthetic disease of adult woman.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Reagent kit for detecting cigarette and wine damnification genetic susceptibility
InactiveCN101354342AMicrobiological testing/measurementMaterial analysis by optical meansFluorescenceXRCC1 Gene
The invention discloses a kit that is used for detecting the genetic predisposition of wine and tobacco damages. The kit comprises particularity primer pairs and particularity fluorescent probe pairs that are used for simultaneously detecting 16 SNP polymorphism genotypes on the genes of ADH2, ALDH2, CYP1A1, CYP2A13, CYP2E1, ENOS, ERCC2, GSTM1, GSTP1, GSTT1, MTHFR, NQO1 and XRCC1 and a routine component that is used for fluorescent quantitative PCR detection, etc. The kit of the invention evaluates the genetic predisposition of wine and tobacco damages by simultaneously detecting the 16 mononucleotide polymorphism locus genotypes that are closely related with the genetic predisposition of wine and tobacco damages.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Reagent kit for detecting man disease genetic susceptibility
The present invention provides a kit for detecting genetic predisposition of adult male syndrome. The kit includes specific primer pairs and specific fluorescent probe pairs for detecting 48 SNP polymorphism genotypes on the genes LPL, TNF-alpha, LEP, ADIPOQ, SOD3, IL3, CTLA4, ENOS, ESR2, ERCC1, MTHFR, MS4A2, XRCC1, ALDH2, TNFA, MTR, CCL5, COMT, GSTP1, PPARG, PARP1, OPG, VDR, PON1, ABCA1, MTRR, ERCC2, AT1R, AGT, CCND1, UCP2, ADH2, ADBR2, APOB, CYP11B2, CYP1A1, CYP2E1, CETP, NQO1, IL6, CYP2A13 at the same time, and normal components for FQ-PCR detection. The kit of the invention evaluates the genetic predisposition of adult male syndrome by detecting the genotypes of the 48 SNP polymorphism sites at the same time which is tightly relative to the genetic predisposition of adult male syndrome.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Non-invasive detection kit for susceptibility gene of basal cell carcinoma
The invention provides a non-invasive detection kit for susceptibility gene of basal cell carcinoma. The kit comprises a specific primer and a DNA sequencing primer which are used for detecting the genotypes of a Mn-SOD gene, a P53 gene and an XRCC1 (X-ray repair cross-complementing group 1) gene, a PCR (Polymerase Chain Reaction) reaction system, a PCR product purification system and a DNA sequencing reaction system, etc. The kit disclosed by the invention is used for evaluating the suffering risk level and degree of basal cell carcinoma in people by detecting the genotypes of three single nucleotide polymorphic sites closely related with occurrence of basal cell carcinoma, and finally guiding Chinese people to pointedly prevent occurrence of basal cell carcinoma from gene dimension according to the gene detection results of a detected person, thereby reducing the morbidity risk rate of basal cell carcinoma. A sample used in the detection kit provided by the invention is a mouth mucosa cell, and a collection method is free of pain and non-invasive, and can prevent cross infection.
Owner:解码(上海)生物医药科技有限公司
Reagent kit for detecting children disease genetic susceptibility
The present invention provides a kit of detecting genetic predisposition of children syndrome. The kit includes specific primer pairs and specific fluorescent probe pairs for detecting 28 SNP polymorphism genotypes on the genes NOS3, CTLA4, ENOS, ERCC1, ERCC2, MTHFR, MTRR, MTR, MS4A2, XRCC1, ALDH2, TNFA, CCL5, PARP1, OPG, VDR, PON1, AGT, CCND1, UCP2, ADH2, ADBR2, APOB, CYP11B2, CYP1A1, CYP2E1, CETP, NQO1 at the same time, and normal components for FQ-PCR detection. The kit of the invention evaluates the genetic predisposition of children syndrome by detecting the genotypes of the 28 SNP polymorphism sites at the same time which is tightly relative to the genetic predisposition of children syndrome.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Reagent kit for detecting pulmonary cancer susceptibility with XRCC1 gene and CYP1A1 gene
InactiveCN101140229AMicrobiological testing/measurementFluorescence/phosphorescenceXRCC1 GeneFluorescence
The present invention discloses a reagent kit to detect lung cancer susceptibility, which comprises a fluorescence probe to synchronously detect specificity tracers and specificity of No. rs25478 SNP locus on gene XRCC1 and No. rs1048943 SNP locus on gene CYP1A1, and a normal assembly to detect fluorescence quantitative PCR and so on. The reagent kit of the present invention synchronously detects and analyzes individual SNPs locus gene carrying type on gene XRCC1 and CYP1A1 to predict susceptibility of the individual to lung cancer.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Reagent kit for detecting susceptibility of cancer of the lungs with SNPs of gene XRCC1 etc.
The invention discloses a regent box for detecting the susceptibility to lung cancer, comprising a specific primer and a specific fluorescent probe which are capable of synchronously detecting an rs1136410 SNP locus on an PARP1 gene, an rs25487 SNP locus on a XRCC1 gene and an rs13181 SNP locus and an rs1799793 SNP locus on an ERCC2 gene, and common components for fluorescent quantitative detection of PCR. The reagent box of invention predicts the susceptibility to lung cancer of an individual by detecting the genotype of genes on the SNP loci of the PARP1 gene, the XRCC1 gene and the ERCC2 gene of the individual.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Medical use of evofosfamide in anti-cancer
Evofosfamide (TH-302) or an analog thereof has a specific inhibitory effect on a cell having a specific gene mutation, in particular on a DNA repair-damaged cell. The cell or tissue has at least one or more gene mutations in BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2, RAD51D, RAD51C, RAD52, RAD54, RAD55, RAD57, FAM175, NBN, Rad50, MER11, p53, NBS1, XRS2, XRCC2,XRCC3, ERCC1, ERCC2, ERCC3, ERCC4, XRCC1, Ku80, MHS6, MGMT, PARP, and ERCC5. For this, a medical use of evofosfamide (TH-302) or an analog thereof in treating tumors or cancer in a cancer patient having the specific gene mutation(s) is provided.
Owner:SHENZHEN ASCENTAWITS PHARM TECH CO LTD
Reagent case for lung carcinoma susceptibility detection through SNPs locus of XRCC1 gene and ERCC2 gene
The invention discloses a reagent box for detecting lung cancer susceptibility. The reagent box comprises a pair of specificity primers for detecting concurrently no. rs25487 SNP site of XRCC1 gene and no. rs1799793 SNP site of ERCC2 gene, a specificity fluorescent probe and an ordinary assembly for fluorescent quantitative PCR detection. The reagent box predicts the susceptibility of individuals on lung cancer by detecting and analyzing currently the type of carried gene at SNPs site of individual XRCC1 and ERCC2 gene.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Reagent case for lung carcinoma susceptibility detection through XRCC1 gene and PARP1 gene
The invention discloses a reagent box for detecting lung cancer susceptibility. The reagent box comprises a pair of specificity primers for detecting concurrently no. rs25487 SNP site of XRCC1 gene and no. rs1136410 SNP site of PARP1 gene, a specificity fluorescent probe and an ordinary assembly for fluorescent quantitative PCR detection. The reagent box predicts the susceptibility of individuals on lung cancer by detecting and analyzing currently the type of carried gene at SNPs site of individual XRCC1 and PARP1 gene.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Reagent kit for detecting susceptibility of cancer of the lungs with SNPs of gene XRCC1 and ERCC2
The present invention discloses a kit used for inspection of susceptibility of lung cancer. The kit comprises not only a specific primer couple and a specific fluorescent probe, which are capable of inspecting at the same time the site SNP of No. rs25487 of gene XRCC1, both the site SNP of No. rs13181 and the site SNP of No. rs1799793 of gene ERCC2, but also a standard component used for fluorescent quantitative PCR. The kit provided by the present invention predicts the individual susceptibility to lung cancer through mutual analysis on the gene type on the site of SNPs of both the gene XRCC1 and gene ERCC2.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Specific primers and liquid chip kit for xrcc1 gene mutation detection
ActiveCN106148486BImprove signal-to-noise ratioEasy to detectMicrobiological testing/measurementDNA/RNA fragmentationXRCC1 GeneMutation detection
The invention discloses an XRCC1 (X-Ray Repair Cross-Complementing Gene 1) gene mutation detection liquid-phase chip and specific primer. The XRCC1 gene mutation detection liquid-phase chip mainly comprises an ASPE primer, microspheres and an amplification primer, wherein the ASPE primer consists of a tag sequence at a 5'-end and a specific primer sequence for a gene mutation site at a 3'-end; the specific primer sequence is SEQ ID NO. 7 and SEQ ID NO. 8 for an A1196G site, SEQ ID NO. 9 and SEQ ID NO. 10 for a C580T site, and SEQ ID NO. 11 and SEQ ID NO. 12 for a G839A site; the microspheres are coated by an anti-tag sequence. The agreement rate of the detection result of the XRCC1 gene mutation detection liquid-phase chip and that of a sequencing method is as high as 100%. Independent or parallel detection on a wild type and a mutation type of multiple mutation sites can be achieved.
Owner:广州益善医学检验所有限公司
Human nucleotide repair protein gene main polymorphism site fast detection method and kit thereof
InactiveCN101186945AStrong specificityIncreased sensitivityMicrobiological testing/measurementXRCC1 GeneRapid testing
The invention discloses a rapid testing method for main polymorphism site of repair protein gene (XRCC1) of human ribonucleotide. According to designed primers of genetic DNA sequence of human chromosome XRCC1, the invention employs polymerase chain reaction (PCR) specific technique to amplify a fragment of DNA sequence respectively including mutation sites of R194W, R280H and R399Q, respectively uses a pair of molecular fluorescent probes to be hybridized with amplified product. Whether a sample includes mutation of R194W, R280H and R399Q is tested by real-time detection of a fluorescent PCR instrument to corresponding specific fluorescent intensity alternation of reaction tubes or by direct detection of specific fluorescent intensity of reaction tubes via a fluorescence spectrophotometer after PCR. The method is convenient and rapid, high in specificity, economic and practical, which is applicable for rapid detection of large-scaled samples. The invention further provides kits applicable for clinical application.
Owner:吕成伟
Anticancer pharmaceutical application of glufosfamide
InactiveCN109833324AOrganic active ingredientsAntineoplastic agentsOrganic acidEsterification reaction
Glufosfamide or analogues thereof have specific inhibitory effects on cells with specific gene variations, specifically, DNA repairs damaged cells, the cells or tissues at least have one or more genemutations of BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2, RAD51D, RAD51C, RAD52, RAD54, RAD55, RAD57, FAM175, NBN, Rad50, MER11, p53, NBS1, XRS2, XRCC2, XRCC3, ERCC1, ERCC2, ERCC3, ERCC4, XRCC1, Ku80, MHS6, MGMT, PARP or ERCC5. The analogues are esters obtained by esterification reaction of one or more hydroxyl groups in glufosfamide molecules with organic acid and inorganic oxyacid; esters obtained by esterification reaction of one or more hydroxyl groups in glufosfamide molecules with amino acid; and salts obtained by reaction of glufosfamide molecules withan acid. Therefore, provided is medical uses of glufosfamide or the analogues thereof in treatment of tumors and cancer diseases of cancer patients with specific gene variations.
Owner:SHENZHEN ASCENTAWITS PHARM TECH CO LTD
Thyroid cancer susceptibility gene detection kit
The invention provides a thyroid cancer susceptibility gene detection kit, which comprises specific primers for detecting XRCC1 gene Arg399Gln locus and hMSH2 gene 13th exon sequence, DNA sequencing primers, a PCR reaction assembly and the like. According to the present invention, the thyroid cancer susceptibility risk levels of subjects are evaluated by detecting the information of the genes XRCC1 and hMSH2 closely related to the occurrence of thyroid cancer, and according to the gene detection results of each subject, the subjects can be guided with the targeted prevention of the occurrenceof thyroid cancer so as to reduce the incidence of thyroid cancer; and the detection result is accurate and reliable, and the method is easy to popularize.
Owner:SHANDONG INT BIOTECH PARK DEV +1
Reagent kit for detecting male tumor disease genetic susceptibility
InactiveCN101354339AMicrobiological testing/measurementMaterial analysis by optical meansFluorescenceERCC2
The invention discloses a kit used for detecting the genetic susceptibility of male tumor diseases. The kit comprises a specific primer pair which detects genotypes of sixteen sites of single nucleotide polymorphism (SNP) in CCND1, CYP2A13, CYP1A1, CYP2E1, ERCC2, GSTM1, GSTP1, GSTT1, MTHFR, NQO1, PARP1, XRCC1 and ERCC1 simultaneously and specified fluorescent probe pairs, conventional components used in fluorescence quantitative PCR detecting, and the like. The kit of the invention evaluates the genetic susceptibility of male tumor diseases by detecting genotypes of sixteen sites of single nucleotide polymorphism which is closely related to the genetic susceptibility of male tumor diseases.
Owner:XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Anticancer medical application of evofosfamide
The invention provides anticancer medical application of evofosfamide. The evofosfamide (TH-302) or an analogue of the evofosfamide has a specific inhibiting effect on specific genetically altered cells, and specifically, cells with damaged DNA repair or tissue at least has one or more gene mutation of BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2, RAD51D, RAD51C,RAD52, RAD54, RAD55, RAD57, FAM175, NBN, Rad50, MER11, p53, NBS1, XRS2, XRCC2, XRCC3, ERCC1, ERCC2, ERCC3, ERCC4, XRCC1, Ku80, MHS6, MGMT, PARP or ERCC5. Therefore, the medical application of the evofosfamide (TH-302) or the analogue of the evofosfamide for treating tumor and cancer diseases of people with cancer of the specific gene mutation is provided.
Owner:SHENZHEN ASCENTAWITS PHARM TECH CO LTD
A set of primers capable of simultaneously detecting ERCC4 and XRCC1 genetic polymorphism, and applications
InactiveCN108949977AGuaranteed reliabilityAmplification program reductionMicrobiological testing/measurementDNA/RNA fragmentationChemo therapyTreatment regimen
The invention discloses a set of primers capable of simultaneously detecting ERCC4 and XRCC1 genetic polymorphism. The primers include a PCR amplification primer and an SNaPshot PCR primer, and simultaneous detection loci include ERCC4 rs1799801 and XRCC1 rs25487; compared with conventional individual amplification performed on multiple loci, amplification programs can be minimized, amplificationcosts can be reduced, and high sensitivity, accuracy and precision can be guaranteed by applying the primers to the selection of clinical chemotherapy drugs, and therefore, the reliability of a methodcan be ensured; and the primers are helpful for doctors to correctly select drugs and treatment schemes for patients, so that the survival rates of cancer patients can be increased.
Owner:KUNMING UNIV OF SCI & TECH
A primer set, reagent and/or kit, system and application thereof for detecting lung cancer chemotherapy-related genes
ActiveCN109517900BClustering is clearImprove accuracyMicrobiological testing/measurementDNA/RNA fragmentationGenes mutationOncology
Owner:SIMCERE DIAGNOSTICS CO LTD +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com